Matthew R. Henn is of Seres Therapeutics, Inc.. Currently has a direct ownership of 65,357 shares of MCRB, which is worth approximately $49,017. The most recent transaction as insider was on May 15, 2024, when has been sold 891 shares (Common Stock) at a price of $0.94 per share, resulting in proceeds of $837. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 65.4K
3.03% 3M change
37.25% 12M change
Total Value Held $49,017

Matthew R. Henn Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 15 2024
SELL
Open market or private sale
$837 $0.94 p/Share
891 Reduced 1.34%
65,357 Common Stock
May 15 2024
BUY
Exercise of conversion of derivative security
-
2,812 Added 4.07%
66,248 Common Stock
Feb 16 2024
SELL
Open market or private sale
$4,503 $1.08 p/Share
4,170 Reduced 6.17%
63,436 Common Stock
Feb 15 2024
BUY
Exercise of conversion of derivative security
-
11,250 Added 14.27%
67,606 Common Stock
Oct 30 2023
SELL
Open market or private sale
$5,246 $1.35 p/Share
3,886 Reduced 6.45%
56,356 Common Stock
Oct 27 2023
BUY
Exercise of conversion of derivative security
-
12,623 Added 17.32%
60,242 Common Stock
Jul 05 2022
BUY
Grant, award, or other acquisition
$150,000 $3.15 p/Share
47,619 Added 50.0%
47,619 Common Stock
Dec 01 2020
SELL
Open market or private sale
$2,523,912 $27.49 p/Share
91,812 Reduced 100.0%
0 Common Stock
Dec 01 2020
BUY
Exercise of conversion of derivative security
$442,158 $5.54 p/Share
79,812 Added 46.5%
91,812 Common Stock
MRH

Matthew R. Henn

Cambridge, MA

Track Institutional and Insider Activities on MCRB

Follow Seres Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MCRB shares.

Notify only if

Insider Trading

Get notified when an Seres Therapeutics, Inc. insider buys or sells MCRB shares.

Notify only if

News

Receive news related to Seres Therapeutics, Inc.

Track Activities on MCRB